The Federal Circuit held that applying inter partes review (IPR) proceedings to patents issued before the America Invents Act does not constitute an unconstitutional taking under the Fifth Amendment, rejecting a major constitutional challenge to the PTAB system.
The Federal Circuit affirmed dismissal of Amgen’s doctrine of equivalents infringement claim, holding that arguments made during patent prosecution create estoppel bars even when those arguments were not strictly necessary to secure allowance of the claims.
The Federal Circuit affirmed invalidity of Enzo’s nucleotide labeling patents for lack of enablement, holding that claims covering tens of thousands of possible labeled polynucleotide embodiments were not enabled when the specification disclosed only a few working examples.
The Federal Circuit reversed a district court’s dismissal of patent claims as ineligible under § 101, applying Berkheimer to hold that well-pleaded factual allegations about how the claimed invention was an unconventional advance must be accepted as true at the 12(b)(6) stage — limiting early
The Supreme Court held that the Lanham Act’s prohibition on registering marks that are immoral or scandalous constitutes an unconstitutional viewpoint-based restriction on speech under the First Amendment.
The Federal Circuit addressed the PTAB’s discretionary authority under § 314(a) to deny IPR petitions based on factors including the stage of parallel district court litigation and the efficiency of institution — affirming the PTAB’s broad discretion in institution decisions and its auth
The Federal Circuit held that state sovereign immunity does not apply in inter partes review proceedings, following the logic of its earlier St. Regis Mohawk Tribe ruling and closing the gap between tribal and state immunity claims at the PTAB.
The Supreme Court held that the federal government is not a ‘person’ eligible to petition for inter partes review, post-grant review, or covered business method review under the America Invents Act.
The Federal Circuit affirmed that patent claims directed to displaying profit-and-loss data on a trading screen were ineligible under § 101 because merely presenting new financial information on a generic display does not solve a technical problem.
The Federal Circuit reversed a district court’s ruling that Endo’s oxymorphone dosing patent was ineligible, holding that claims directed to a specific method of treating specific patients with specific dosages are not merely abstract natural laws.